Neurogenic inflammation: biochemical markers, genetic control and diseases
Neurogenic inflammation is a pathological process based on bidirectional interactions between cells of the nervous and immune systems as well as on a wide range of biologically active substances.Aim. Basing on scientific publications and information provided in databases, to analyze markers of neuro...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
A. N. Kucher [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch ; Russisch |
| Erschienen: |
2020 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
In: Бюллетень сибирской медицины - Siberian State Medical University (Tomsk), 2016, 19(2020), 2, Seite 171-181 |
|---|---|
| Übergeordnetes Werk: |
volume:19 ; year:2020 ; number:2 ; pages:171-181 |
| Links: |
Link aufrufen |
|---|
| DOI / URN: |
10.20538/1682-0363-2020-2-171-181 |
|---|
| Katalog-ID: |
DOAJ084316993 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ084316993 | ||
| 003 | DE-627 | ||
| 005 | 20230410115626.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230311s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.20538/1682-0363-2020-2-171-181 |2 doi | |
| 035 | |a (DE-627)DOAJ084316993 | ||
| 035 | |a (DE-599)DOAJed7501108b56484ba243d8a0c1a2328b | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng |a rus | ||
| 100 | 0 | |a A. N. Kucher |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Neurogenic inflammation: biochemical markers, genetic control and diseases |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Neurogenic inflammation is a pathological process based on bidirectional interactions between cells of the nervous and immune systems as well as on a wide range of biologically active substances.Aim. Basing on scientific publications and information provided in databases, to analyze markers of neurogenic inflammation (biochemical, genetic) and characterize their involvement in the pathogenesis of diseases of various organ systems.Results. Neurogenic inflammation that occurs during the development of various diseases (asthma, urticaria, atopic dermatitis, psoriasis, rheumatoid arthritis, pain syndrome, interstitial cystitis, colitis, etc.) is characterized by common stages and pathophysiologically active substances. Mediators released by nerve cells (substance P, calcitonin gene-related peptide, vasoactive peptide), acting on specific receptors, contribute to mast cell degranulation with the release of a complex of biologically active substances (histamine, tryptase, nerve growth factor, etc.), which activate inflammatory processes. Biologically active substances and receptors significant for the development of neurogenic inflammation are under genetic control. At the same time, there are overlaps of the spectrum of diseases for which importance in the pathogenesis of neurogenic inflammation is proved and an association between variants of neurogenic inflammation genes. This makes it possible to conclude that the course of neurogenic inflammation will depend not only on the etiological factors, but also on the genetic features of key molecules involved in neurogenic inflammation processes. The similarity of the pathogenetic links of neurogenic inflammation (at the genetic and biochemical levels) in various pathologies may underlie the formation of comorbid conditions.Conclusion. Understanding the biochemical and genetic components of the development of neurogenic inflammation is of interest for prevention and treatment of diseases (including comorbid ones) based on this pathological process. | ||
| 650 | 4 | |a нейрогенное воспаление | |
| 650 | 4 | |a генетика | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 773 | 0 | 8 | |i In |t Бюллетень сибирской медицины |d Siberian State Medical University (Tomsk), 2016 |g 19(2020), 2, Seite 171-181 |w (DE-627)1760628204 |x 18193684 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2020 |g number:2 |g pages:171-181 |
| 856 | 4 | 0 | |u https://doi.org/10.20538/1682-0363-2020-2-171-181 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/ed7501108b56484ba243d8a0c1a2328b |z kostenfrei |
| 856 | 4 | 0 | |u https://bulletin.ssmu.ru/jour/article/view/2874 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1682-0363 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1819-3684 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2020 |e 2 |h 171-181 | ||
| author_variant |
a n k ank |
|---|---|
| matchkey_str |
article:18193684:2020----::ergncnlmainiceiamreseeic |
| hierarchy_sort_str |
2020 |
| publishDate |
2020 |
| allfields |
10.20538/1682-0363-2020-2-171-181 doi (DE-627)DOAJ084316993 (DE-599)DOAJed7501108b56484ba243d8a0c1a2328b DE-627 ger DE-627 rakwb eng rus A. N. Kucher verfasserin aut Neurogenic inflammation: biochemical markers, genetic control and diseases 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Neurogenic inflammation is a pathological process based on bidirectional interactions between cells of the nervous and immune systems as well as on a wide range of biologically active substances.Aim. Basing on scientific publications and information provided in databases, to analyze markers of neurogenic inflammation (biochemical, genetic) and characterize their involvement in the pathogenesis of diseases of various organ systems.Results. Neurogenic inflammation that occurs during the development of various diseases (asthma, urticaria, atopic dermatitis, psoriasis, rheumatoid arthritis, pain syndrome, interstitial cystitis, colitis, etc.) is characterized by common stages and pathophysiologically active substances. Mediators released by nerve cells (substance P, calcitonin gene-related peptide, vasoactive peptide), acting on specific receptors, contribute to mast cell degranulation with the release of a complex of biologically active substances (histamine, tryptase, nerve growth factor, etc.), which activate inflammatory processes. Biologically active substances and receptors significant for the development of neurogenic inflammation are under genetic control. At the same time, there are overlaps of the spectrum of diseases for which importance in the pathogenesis of neurogenic inflammation is proved and an association between variants of neurogenic inflammation genes. This makes it possible to conclude that the course of neurogenic inflammation will depend not only on the etiological factors, but also on the genetic features of key molecules involved in neurogenic inflammation processes. The similarity of the pathogenetic links of neurogenic inflammation (at the genetic and biochemical levels) in various pathologies may underlie the formation of comorbid conditions.Conclusion. Understanding the biochemical and genetic components of the development of neurogenic inflammation is of interest for prevention and treatment of diseases (including comorbid ones) based on this pathological process. нейрогенное воспаление генетика Medicine R In Бюллетень сибирской медицины Siberian State Medical University (Tomsk), 2016 19(2020), 2, Seite 171-181 (DE-627)1760628204 18193684 nnns volume:19 year:2020 number:2 pages:171-181 https://doi.org/10.20538/1682-0363-2020-2-171-181 kostenfrei https://doaj.org/article/ed7501108b56484ba243d8a0c1a2328b kostenfrei https://bulletin.ssmu.ru/jour/article/view/2874 kostenfrei https://doaj.org/toc/1682-0363 Journal toc kostenfrei https://doaj.org/toc/1819-3684 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 19 2020 2 171-181 |
| spelling |
10.20538/1682-0363-2020-2-171-181 doi (DE-627)DOAJ084316993 (DE-599)DOAJed7501108b56484ba243d8a0c1a2328b DE-627 ger DE-627 rakwb eng rus A. N. Kucher verfasserin aut Neurogenic inflammation: biochemical markers, genetic control and diseases 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Neurogenic inflammation is a pathological process based on bidirectional interactions between cells of the nervous and immune systems as well as on a wide range of biologically active substances.Aim. Basing on scientific publications and information provided in databases, to analyze markers of neurogenic inflammation (biochemical, genetic) and characterize their involvement in the pathogenesis of diseases of various organ systems.Results. Neurogenic inflammation that occurs during the development of various diseases (asthma, urticaria, atopic dermatitis, psoriasis, rheumatoid arthritis, pain syndrome, interstitial cystitis, colitis, etc.) is characterized by common stages and pathophysiologically active substances. Mediators released by nerve cells (substance P, calcitonin gene-related peptide, vasoactive peptide), acting on specific receptors, contribute to mast cell degranulation with the release of a complex of biologically active substances (histamine, tryptase, nerve growth factor, etc.), which activate inflammatory processes. Biologically active substances and receptors significant for the development of neurogenic inflammation are under genetic control. At the same time, there are overlaps of the spectrum of diseases for which importance in the pathogenesis of neurogenic inflammation is proved and an association between variants of neurogenic inflammation genes. This makes it possible to conclude that the course of neurogenic inflammation will depend not only on the etiological factors, but also on the genetic features of key molecules involved in neurogenic inflammation processes. The similarity of the pathogenetic links of neurogenic inflammation (at the genetic and biochemical levels) in various pathologies may underlie the formation of comorbid conditions.Conclusion. Understanding the biochemical and genetic components of the development of neurogenic inflammation is of interest for prevention and treatment of diseases (including comorbid ones) based on this pathological process. нейрогенное воспаление генетика Medicine R In Бюллетень сибирской медицины Siberian State Medical University (Tomsk), 2016 19(2020), 2, Seite 171-181 (DE-627)1760628204 18193684 nnns volume:19 year:2020 number:2 pages:171-181 https://doi.org/10.20538/1682-0363-2020-2-171-181 kostenfrei https://doaj.org/article/ed7501108b56484ba243d8a0c1a2328b kostenfrei https://bulletin.ssmu.ru/jour/article/view/2874 kostenfrei https://doaj.org/toc/1682-0363 Journal toc kostenfrei https://doaj.org/toc/1819-3684 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 19 2020 2 171-181 |
| allfields_unstemmed |
10.20538/1682-0363-2020-2-171-181 doi (DE-627)DOAJ084316993 (DE-599)DOAJed7501108b56484ba243d8a0c1a2328b DE-627 ger DE-627 rakwb eng rus A. N. Kucher verfasserin aut Neurogenic inflammation: biochemical markers, genetic control and diseases 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Neurogenic inflammation is a pathological process based on bidirectional interactions between cells of the nervous and immune systems as well as on a wide range of biologically active substances.Aim. Basing on scientific publications and information provided in databases, to analyze markers of neurogenic inflammation (biochemical, genetic) and characterize their involvement in the pathogenesis of diseases of various organ systems.Results. Neurogenic inflammation that occurs during the development of various diseases (asthma, urticaria, atopic dermatitis, psoriasis, rheumatoid arthritis, pain syndrome, interstitial cystitis, colitis, etc.) is characterized by common stages and pathophysiologically active substances. Mediators released by nerve cells (substance P, calcitonin gene-related peptide, vasoactive peptide), acting on specific receptors, contribute to mast cell degranulation with the release of a complex of biologically active substances (histamine, tryptase, nerve growth factor, etc.), which activate inflammatory processes. Biologically active substances and receptors significant for the development of neurogenic inflammation are under genetic control. At the same time, there are overlaps of the spectrum of diseases for which importance in the pathogenesis of neurogenic inflammation is proved and an association between variants of neurogenic inflammation genes. This makes it possible to conclude that the course of neurogenic inflammation will depend not only on the etiological factors, but also on the genetic features of key molecules involved in neurogenic inflammation processes. The similarity of the pathogenetic links of neurogenic inflammation (at the genetic and biochemical levels) in various pathologies may underlie the formation of comorbid conditions.Conclusion. Understanding the biochemical and genetic components of the development of neurogenic inflammation is of interest for prevention and treatment of diseases (including comorbid ones) based on this pathological process. нейрогенное воспаление генетика Medicine R In Бюллетень сибирской медицины Siberian State Medical University (Tomsk), 2016 19(2020), 2, Seite 171-181 (DE-627)1760628204 18193684 nnns volume:19 year:2020 number:2 pages:171-181 https://doi.org/10.20538/1682-0363-2020-2-171-181 kostenfrei https://doaj.org/article/ed7501108b56484ba243d8a0c1a2328b kostenfrei https://bulletin.ssmu.ru/jour/article/view/2874 kostenfrei https://doaj.org/toc/1682-0363 Journal toc kostenfrei https://doaj.org/toc/1819-3684 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 19 2020 2 171-181 |
| allfieldsGer |
10.20538/1682-0363-2020-2-171-181 doi (DE-627)DOAJ084316993 (DE-599)DOAJed7501108b56484ba243d8a0c1a2328b DE-627 ger DE-627 rakwb eng rus A. N. Kucher verfasserin aut Neurogenic inflammation: biochemical markers, genetic control and diseases 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Neurogenic inflammation is a pathological process based on bidirectional interactions between cells of the nervous and immune systems as well as on a wide range of biologically active substances.Aim. Basing on scientific publications and information provided in databases, to analyze markers of neurogenic inflammation (biochemical, genetic) and characterize their involvement in the pathogenesis of diseases of various organ systems.Results. Neurogenic inflammation that occurs during the development of various diseases (asthma, urticaria, atopic dermatitis, psoriasis, rheumatoid arthritis, pain syndrome, interstitial cystitis, colitis, etc.) is characterized by common stages and pathophysiologically active substances. Mediators released by nerve cells (substance P, calcitonin gene-related peptide, vasoactive peptide), acting on specific receptors, contribute to mast cell degranulation with the release of a complex of biologically active substances (histamine, tryptase, nerve growth factor, etc.), which activate inflammatory processes. Biologically active substances and receptors significant for the development of neurogenic inflammation are under genetic control. At the same time, there are overlaps of the spectrum of diseases for which importance in the pathogenesis of neurogenic inflammation is proved and an association between variants of neurogenic inflammation genes. This makes it possible to conclude that the course of neurogenic inflammation will depend not only on the etiological factors, but also on the genetic features of key molecules involved in neurogenic inflammation processes. The similarity of the pathogenetic links of neurogenic inflammation (at the genetic and biochemical levels) in various pathologies may underlie the formation of comorbid conditions.Conclusion. Understanding the biochemical and genetic components of the development of neurogenic inflammation is of interest for prevention and treatment of diseases (including comorbid ones) based on this pathological process. нейрогенное воспаление генетика Medicine R In Бюллетень сибирской медицины Siberian State Medical University (Tomsk), 2016 19(2020), 2, Seite 171-181 (DE-627)1760628204 18193684 nnns volume:19 year:2020 number:2 pages:171-181 https://doi.org/10.20538/1682-0363-2020-2-171-181 kostenfrei https://doaj.org/article/ed7501108b56484ba243d8a0c1a2328b kostenfrei https://bulletin.ssmu.ru/jour/article/view/2874 kostenfrei https://doaj.org/toc/1682-0363 Journal toc kostenfrei https://doaj.org/toc/1819-3684 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 19 2020 2 171-181 |
| allfieldsSound |
10.20538/1682-0363-2020-2-171-181 doi (DE-627)DOAJ084316993 (DE-599)DOAJed7501108b56484ba243d8a0c1a2328b DE-627 ger DE-627 rakwb eng rus A. N. Kucher verfasserin aut Neurogenic inflammation: biochemical markers, genetic control and diseases 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Neurogenic inflammation is a pathological process based on bidirectional interactions between cells of the nervous and immune systems as well as on a wide range of biologically active substances.Aim. Basing on scientific publications and information provided in databases, to analyze markers of neurogenic inflammation (biochemical, genetic) and characterize their involvement in the pathogenesis of diseases of various organ systems.Results. Neurogenic inflammation that occurs during the development of various diseases (asthma, urticaria, atopic dermatitis, psoriasis, rheumatoid arthritis, pain syndrome, interstitial cystitis, colitis, etc.) is characterized by common stages and pathophysiologically active substances. Mediators released by nerve cells (substance P, calcitonin gene-related peptide, vasoactive peptide), acting on specific receptors, contribute to mast cell degranulation with the release of a complex of biologically active substances (histamine, tryptase, nerve growth factor, etc.), which activate inflammatory processes. Biologically active substances and receptors significant for the development of neurogenic inflammation are under genetic control. At the same time, there are overlaps of the spectrum of diseases for which importance in the pathogenesis of neurogenic inflammation is proved and an association between variants of neurogenic inflammation genes. This makes it possible to conclude that the course of neurogenic inflammation will depend not only on the etiological factors, but also on the genetic features of key molecules involved in neurogenic inflammation processes. The similarity of the pathogenetic links of neurogenic inflammation (at the genetic and biochemical levels) in various pathologies may underlie the formation of comorbid conditions.Conclusion. Understanding the biochemical and genetic components of the development of neurogenic inflammation is of interest for prevention and treatment of diseases (including comorbid ones) based on this pathological process. нейрогенное воспаление генетика Medicine R In Бюллетень сибирской медицины Siberian State Medical University (Tomsk), 2016 19(2020), 2, Seite 171-181 (DE-627)1760628204 18193684 nnns volume:19 year:2020 number:2 pages:171-181 https://doi.org/10.20538/1682-0363-2020-2-171-181 kostenfrei https://doaj.org/article/ed7501108b56484ba243d8a0c1a2328b kostenfrei https://bulletin.ssmu.ru/jour/article/view/2874 kostenfrei https://doaj.org/toc/1682-0363 Journal toc kostenfrei https://doaj.org/toc/1819-3684 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 19 2020 2 171-181 |
| language |
English Russian |
| source |
In Бюллетень сибирской медицины 19(2020), 2, Seite 171-181 volume:19 year:2020 number:2 pages:171-181 |
| sourceStr |
In Бюллетень сибирской медицины 19(2020), 2, Seite 171-181 volume:19 year:2020 number:2 pages:171-181 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
нейрогенное воспаление генетика Medicine R |
| isfreeaccess_bool |
true |
| container_title |
Бюллетень сибирской медицины |
| authorswithroles_txt_mv |
A. N. Kucher @@aut@@ |
| publishDateDaySort_date |
2020-01-01T00:00:00Z |
| hierarchy_top_id |
1760628204 |
| id |
DOAJ084316993 |
| language_de |
englisch russisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ084316993</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230410115626.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230311s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.20538/1682-0363-2020-2-171-181</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ084316993</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJed7501108b56484ba243d8a0c1a2328b</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield><subfield code="a">rus</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">A. N. Kucher</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Neurogenic inflammation: biochemical markers, genetic control and diseases</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Neurogenic inflammation is a pathological process based on bidirectional interactions between cells of the nervous and immune systems as well as on a wide range of biologically active substances.Aim. Basing on scientific publications and information provided in databases, to analyze markers of neurogenic inflammation (biochemical, genetic) and characterize their involvement in the pathogenesis of diseases of various organ systems.Results. Neurogenic inflammation that occurs during the development of various diseases (asthma, urticaria, atopic dermatitis, psoriasis, rheumatoid arthritis, pain syndrome, interstitial cystitis, colitis, etc.) is characterized by common stages and pathophysiologically active substances. Mediators released by nerve cells (substance P, calcitonin gene-related peptide, vasoactive peptide), acting on specific receptors, contribute to mast cell degranulation with the release of a complex of biologically active substances (histamine, tryptase, nerve growth factor, etc.), which activate inflammatory processes. Biologically active substances and receptors significant for the development of neurogenic inflammation are under genetic control. At the same time, there are overlaps of the spectrum of diseases for which importance in the pathogenesis of neurogenic inflammation is proved and an association between variants of neurogenic inflammation genes. This makes it possible to conclude that the course of neurogenic inflammation will depend not only on the etiological factors, but also on the genetic features of key molecules involved in neurogenic inflammation processes. The similarity of the pathogenetic links of neurogenic inflammation (at the genetic and biochemical levels) in various pathologies may underlie the formation of comorbid conditions.Conclusion. Understanding the biochemical and genetic components of the development of neurogenic inflammation is of interest for prevention and treatment of diseases (including comorbid ones) based on this pathological process.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">нейрогенное воспаление</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">генетика</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Бюллетень сибирской медицины</subfield><subfield code="d">Siberian State Medical University (Tomsk), 2016</subfield><subfield code="g">19(2020), 2, Seite 171-181</subfield><subfield code="w">(DE-627)1760628204</subfield><subfield code="x">18193684</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:19</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:171-181</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.20538/1682-0363-2020-2-171-181</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/ed7501108b56484ba243d8a0c1a2328b</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://bulletin.ssmu.ru/jour/article/view/2874</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1682-0363</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1819-3684</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">19</subfield><subfield code="j">2020</subfield><subfield code="e">2</subfield><subfield code="h">171-181</subfield></datafield></record></collection>
|
| author |
A. N. Kucher |
| spellingShingle |
A. N. Kucher misc нейрогенное воспаление misc генетика misc Medicine misc R Neurogenic inflammation: biochemical markers, genetic control and diseases |
| authorStr |
A. N. Kucher |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)1760628204 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
DOAJ |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
18193684 |
| topic_title |
Neurogenic inflammation: biochemical markers, genetic control and diseases нейрогенное воспаление генетика |
| topic |
misc нейрогенное воспаление misc генетика misc Medicine misc R |
| topic_unstemmed |
misc нейрогенное воспаление misc генетика misc Medicine misc R |
| topic_browse |
misc нейрогенное воспаление misc генетика misc Medicine misc R |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Бюллетень сибирской медицины |
| hierarchy_parent_id |
1760628204 |
| hierarchy_top_title |
Бюллетень сибирской медицины |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)1760628204 |
| title |
Neurogenic inflammation: biochemical markers, genetic control and diseases |
| ctrlnum |
(DE-627)DOAJ084316993 (DE-599)DOAJed7501108b56484ba243d8a0c1a2328b |
| title_full |
Neurogenic inflammation: biochemical markers, genetic control and diseases |
| author_sort |
A. N. Kucher |
| journal |
Бюллетень сибирской медицины |
| journalStr |
Бюллетень сибирской медицины |
| lang_code |
eng rus |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2020 |
| contenttype_str_mv |
txt |
| container_start_page |
171 |
| author_browse |
A. N. Kucher |
| container_volume |
19 |
| format_se |
Elektronische Aufsätze |
| author-letter |
A. N. Kucher |
| doi_str_mv |
10.20538/1682-0363-2020-2-171-181 |
| title_sort |
neurogenic inflammation: biochemical markers, genetic control and diseases |
| title_auth |
Neurogenic inflammation: biochemical markers, genetic control and diseases |
| abstract |
Neurogenic inflammation is a pathological process based on bidirectional interactions between cells of the nervous and immune systems as well as on a wide range of biologically active substances.Aim. Basing on scientific publications and information provided in databases, to analyze markers of neurogenic inflammation (biochemical, genetic) and characterize their involvement in the pathogenesis of diseases of various organ systems.Results. Neurogenic inflammation that occurs during the development of various diseases (asthma, urticaria, atopic dermatitis, psoriasis, rheumatoid arthritis, pain syndrome, interstitial cystitis, colitis, etc.) is characterized by common stages and pathophysiologically active substances. Mediators released by nerve cells (substance P, calcitonin gene-related peptide, vasoactive peptide), acting on specific receptors, contribute to mast cell degranulation with the release of a complex of biologically active substances (histamine, tryptase, nerve growth factor, etc.), which activate inflammatory processes. Biologically active substances and receptors significant for the development of neurogenic inflammation are under genetic control. At the same time, there are overlaps of the spectrum of diseases for which importance in the pathogenesis of neurogenic inflammation is proved and an association between variants of neurogenic inflammation genes. This makes it possible to conclude that the course of neurogenic inflammation will depend not only on the etiological factors, but also on the genetic features of key molecules involved in neurogenic inflammation processes. The similarity of the pathogenetic links of neurogenic inflammation (at the genetic and biochemical levels) in various pathologies may underlie the formation of comorbid conditions.Conclusion. Understanding the biochemical and genetic components of the development of neurogenic inflammation is of interest for prevention and treatment of diseases (including comorbid ones) based on this pathological process. |
| abstractGer |
Neurogenic inflammation is a pathological process based on bidirectional interactions between cells of the nervous and immune systems as well as on a wide range of biologically active substances.Aim. Basing on scientific publications and information provided in databases, to analyze markers of neurogenic inflammation (biochemical, genetic) and characterize their involvement in the pathogenesis of diseases of various organ systems.Results. Neurogenic inflammation that occurs during the development of various diseases (asthma, urticaria, atopic dermatitis, psoriasis, rheumatoid arthritis, pain syndrome, interstitial cystitis, colitis, etc.) is characterized by common stages and pathophysiologically active substances. Mediators released by nerve cells (substance P, calcitonin gene-related peptide, vasoactive peptide), acting on specific receptors, contribute to mast cell degranulation with the release of a complex of biologically active substances (histamine, tryptase, nerve growth factor, etc.), which activate inflammatory processes. Biologically active substances and receptors significant for the development of neurogenic inflammation are under genetic control. At the same time, there are overlaps of the spectrum of diseases for which importance in the pathogenesis of neurogenic inflammation is proved and an association between variants of neurogenic inflammation genes. This makes it possible to conclude that the course of neurogenic inflammation will depend not only on the etiological factors, but also on the genetic features of key molecules involved in neurogenic inflammation processes. The similarity of the pathogenetic links of neurogenic inflammation (at the genetic and biochemical levels) in various pathologies may underlie the formation of comorbid conditions.Conclusion. Understanding the biochemical and genetic components of the development of neurogenic inflammation is of interest for prevention and treatment of diseases (including comorbid ones) based on this pathological process. |
| abstract_unstemmed |
Neurogenic inflammation is a pathological process based on bidirectional interactions between cells of the nervous and immune systems as well as on a wide range of biologically active substances.Aim. Basing on scientific publications and information provided in databases, to analyze markers of neurogenic inflammation (biochemical, genetic) and characterize their involvement in the pathogenesis of diseases of various organ systems.Results. Neurogenic inflammation that occurs during the development of various diseases (asthma, urticaria, atopic dermatitis, psoriasis, rheumatoid arthritis, pain syndrome, interstitial cystitis, colitis, etc.) is characterized by common stages and pathophysiologically active substances. Mediators released by nerve cells (substance P, calcitonin gene-related peptide, vasoactive peptide), acting on specific receptors, contribute to mast cell degranulation with the release of a complex of biologically active substances (histamine, tryptase, nerve growth factor, etc.), which activate inflammatory processes. Biologically active substances and receptors significant for the development of neurogenic inflammation are under genetic control. At the same time, there are overlaps of the spectrum of diseases for which importance in the pathogenesis of neurogenic inflammation is proved and an association between variants of neurogenic inflammation genes. This makes it possible to conclude that the course of neurogenic inflammation will depend not only on the etiological factors, but also on the genetic features of key molecules involved in neurogenic inflammation processes. The similarity of the pathogenetic links of neurogenic inflammation (at the genetic and biochemical levels) in various pathologies may underlie the formation of comorbid conditions.Conclusion. Understanding the biochemical and genetic components of the development of neurogenic inflammation is of interest for prevention and treatment of diseases (including comorbid ones) based on this pathological process. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ |
| container_issue |
2 |
| title_short |
Neurogenic inflammation: biochemical markers, genetic control and diseases |
| url |
https://doi.org/10.20538/1682-0363-2020-2-171-181 https://doaj.org/article/ed7501108b56484ba243d8a0c1a2328b https://bulletin.ssmu.ru/jour/article/view/2874 https://doaj.org/toc/1682-0363 https://doaj.org/toc/1819-3684 |
| remote_bool |
true |
| ppnlink |
1760628204 |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.20538/1682-0363-2020-2-171-181 |
| up_date |
2024-07-03T22:22:44.967Z |
| _version_ |
1803598288616685568 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ084316993</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230410115626.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230311s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.20538/1682-0363-2020-2-171-181</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ084316993</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJed7501108b56484ba243d8a0c1a2328b</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield><subfield code="a">rus</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">A. N. Kucher</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Neurogenic inflammation: biochemical markers, genetic control and diseases</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Neurogenic inflammation is a pathological process based on bidirectional interactions between cells of the nervous and immune systems as well as on a wide range of biologically active substances.Aim. Basing on scientific publications and information provided in databases, to analyze markers of neurogenic inflammation (biochemical, genetic) and characterize their involvement in the pathogenesis of diseases of various organ systems.Results. Neurogenic inflammation that occurs during the development of various diseases (asthma, urticaria, atopic dermatitis, psoriasis, rheumatoid arthritis, pain syndrome, interstitial cystitis, colitis, etc.) is characterized by common stages and pathophysiologically active substances. Mediators released by nerve cells (substance P, calcitonin gene-related peptide, vasoactive peptide), acting on specific receptors, contribute to mast cell degranulation with the release of a complex of biologically active substances (histamine, tryptase, nerve growth factor, etc.), which activate inflammatory processes. Biologically active substances and receptors significant for the development of neurogenic inflammation are under genetic control. At the same time, there are overlaps of the spectrum of diseases for which importance in the pathogenesis of neurogenic inflammation is proved and an association between variants of neurogenic inflammation genes. This makes it possible to conclude that the course of neurogenic inflammation will depend not only on the etiological factors, but also on the genetic features of key molecules involved in neurogenic inflammation processes. The similarity of the pathogenetic links of neurogenic inflammation (at the genetic and biochemical levels) in various pathologies may underlie the formation of comorbid conditions.Conclusion. Understanding the biochemical and genetic components of the development of neurogenic inflammation is of interest for prevention and treatment of diseases (including comorbid ones) based on this pathological process.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">нейрогенное воспаление</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">генетика</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Бюллетень сибирской медицины</subfield><subfield code="d">Siberian State Medical University (Tomsk), 2016</subfield><subfield code="g">19(2020), 2, Seite 171-181</subfield><subfield code="w">(DE-627)1760628204</subfield><subfield code="x">18193684</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:19</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:171-181</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.20538/1682-0363-2020-2-171-181</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/ed7501108b56484ba243d8a0c1a2328b</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://bulletin.ssmu.ru/jour/article/view/2874</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1682-0363</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1819-3684</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">19</subfield><subfield code="j">2020</subfield><subfield code="e">2</subfield><subfield code="h">171-181</subfield></datafield></record></collection>
|
| score |
7.401078 |